Research ExplorerScientific StaffKerstin Schütze Publications

Kerstin Schütze

graph of relations
Affiliations
1 - 9 out of 9Page size: 50

Publications

  1. 2023

  2. MAP kinase activating death domain deficiency is a novel cause of impaired lymphocyte cytotoxicity

    Schütze, K., Groß, M., Cornils, K., Wustrau, K., Schneppenheim, S., Lenhartz, H., Korenke, G-C., Janka, G., Ledig, S., Müller, I., Ehl, S. & Lehmberg, K., 25.04.2023, In: BLOOD ADV. 7, 8, p. 1531-1535 5 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. 2022

  4. Immune Ablation and Stem Cell Rescue in Two Pediatric Patients with Progressive Severe Chronic Graft-Versus-Host Disease

    Kloehn, J., Kruchen, A., Schütze, K., Wustrau, K., Schrum, J. & Müller, I., 06.12.2022, In: INT J MOL SCI. 23, 23, 15403.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. 2020

  6. Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)

    Hambach, J., Riecken, K., Cichutek, S., Schütze, K., Albrecht, B., Petry, K., Röckendorf, J. L., Baum, N., Kröger, N., Hansen, T., Schuch, G., Haag, F., Adam, G., Fehse, B., Bannas, P. & Koch-Nolte, F., 29.01.2020, In: CELLS-BASEL. 9, 2

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

    Schriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., Fehse, B., Röckendorf, J. L., Schmid, J., Albrecht, B., Pinnschmidt, H., Ayuk, F., Kröger, N., Binder, M., Schuch, G., Hansen, T., Haag, F., Adam, G., Koch-Nolte, F. & Bannas, P., 2020, In: THERANOSTICS. 10, 6, p. 2645-2658 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. 2019

  9. Nanobody-targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies

    Tintelnot, J., Baum, N., Schultheiss, C., Braig, F., Trentmann, M., Finter, J., Fumey, W., Bannas, P., Fehse, B., Riecken, K., Schütze, K., Bokemeyer, C., Rösner, T., Valerius, T., Peipp, M., Koch-Nolte, F. & Binder, M., 04.2019, In: MOL CANCER THER. 18, 4, p. 823-833 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. 2018

  11. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells

    Schütze, K., Petry, K., Hambach, J., Schuster, N., Fumey, W., Schriewer, L., Rockendorf, J., Menzel, S., Albrecht, B., Haag, F., Stortelers, C., Bannas, P. & Koch-Nolte, F., 19.11.2018, In: FRONT IMMUNOL. 9, p. 2553

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. 2017

  13. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo

    Fumey, W., Koenigsdorf, J., Kunick, V., Menzel, S., Schütze, K., Unger, M., Schriewer, L., Haag, F., Adam, G., Oberle, A., Binder, M., Fliegert, R., Guse, A., Zhao, Y. J., Cheung Lee, H., Malavasi, F., Goldbaum, F., van Hegelsom, R., Stortelers, C., Bannas, P. & Koch-Nolte, F., 30.10.2017, In: SCI REP-UK. 7, 1, p. 14289

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection

    Oberle, A., Brandt, A., Alawi, M., Langebrake, C., Janjetovic, S., Wolschke, C., Schütze, K., Bannas, P., Kröger, N., Koch-Nolte, F., Bokemeyer, C. & Binder, M., 09.2017, In: HAEMATOLOGICA. 102, 9, p. e368-e370

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  15. 2015

  16. Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection

    Bannas, P., Lenz, A., Kunick, V., Well, L., Fumey, W., Rissiek, B., Haag, F., Schmid, J., Schütze, K., Eichhoff, A., Trepel, M., Adam, G., Ittrich, H. & Koch-Nolte, F., 27.04.2015, In: CONTRAST MEDIA MOL I. 10, 5, p. 367-378

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review